GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (OTCPK:BIOAF) » Definitions » Quick Ratio

Bioasis Technologies (Bioasis Technologies) Quick Ratio : 0.11 (As of Nov. 2022)


View and export this data going back to 2009. Start your Free Trial

What is Bioasis Technologies Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Bioasis Technologies's quick ratio for the quarter that ended in Nov. 2022 was 0.11.

Bioasis Technologies has a quick ratio of 0.11. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Bioasis Technologies's Quick Ratio or its related term are showing as below:

BIOAF's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.515
* Ranked among companies with meaningful Quick Ratio only.

Bioasis Technologies Quick Ratio Historical Data

The historical data trend for Bioasis Technologies's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Quick Ratio Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.01 1.09 0.26 1.61 0.70

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.04 0.70 0.38 0.26 0.11

Competitive Comparison of Bioasis Technologies's Quick Ratio

For the Biotechnology subindustry, Bioasis Technologies's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioasis Technologies's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Quick Ratio falls into.



Bioasis Technologies Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Bioasis Technologies's Quick Ratio for the fiscal year that ended in Feb. 2022 is calculated as

Quick Ratio (A: Feb. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(1.658-0)/2.352
=0.70

Bioasis Technologies's Quick Ratio for the quarter that ended in Nov. 2022 is calculated as

Quick Ratio (Q: Nov. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.285-0)/2.678
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioasis Technologies  (OTCPK:BIOAF) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Bioasis Technologies Quick Ratio Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioasis Technologies (Bioasis Technologies) Business Description

Traded in Other Exchanges
N/A
Address
157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (Bioasis Technologies) Headlines